The global neuroendocrine carcinoma market size was valued at 1.56 billion in 2021 and is expected to reach 3.11 billion in 2030 expanding at a compound annual growth rate (CAGR) of 7.96% from 2022 to 2030.
Cancers that originate in specialized cells known as neuroendocrine cells might be referred to as neuroendocrine tumors. These cells have characteristics that are equivalent to those of nerve cells and cells that produce hormones. These tumors are able to develop in any part of the body. This illness can be deadly if it is not caught and treated in its early stages. Therefore, getting an accurate diagnosis as soon as possible and beginning therapy as soon as possible are both extremely important factors that need to be taken into account. There are a lot of companies competing in the market for neuroendocrine carcinoma, and a lot of those companies are trying to produce goods and methods that can assist in the early identification of neuroendocrine carcinoma. Due to this, the market for neuroendocrine carcinoma may have growth that is encouraging in the future.
There are several primary factors that are contributing to the expansion of the neuroendocrine carcinoma treatment market. These factors include an increasing incidence rate of cancer disease, an increasing rate of product approval, the incorporation of artificial intelligence for treating and diagnosing disease, and awareness campaigns by governments for early detection.
There is more than one approach that may be used to treat cancer. When it comes to treating neuroendocrine tumours, targeted therapy is quickly becoming one of the most popular therapeutic choices. Targeted therapy is a strategy that has proven to be successful in the treatment of several malignancies Because of this the utilization of targeted NET treatments would expand throughout the course of the forecast period, which is further anticipated to drive the expansion of the market. Even while somatostatins are successful in treating certain kinds of pituitary tumours, it is anticipated that regulatory authorization for NET would further drive its investigation as a combination therapy with targeted medications. Another somatostatin analogue being investigated for use in the treatment of NET is called pasireotide. Because of their efficacy in the long-term management of the condition, somatostatin analogs are the treatment of choice for chronic disease control. In addition, the monoclonal antibody known as Avastin (Bevacizumab) is now being investigated for its potential use in the treatment of carcinoid tumours. Patients who have carcinoid tumours in the stomach and high gastrin levels have seen their tumours diminish after using the drug netazepide, which is an antagonist for the gastrin/CCK2 receptor. Because of the fact that it is a rare condition, the regulatory authorities are concentrating their efforts on providing possible therapeutic candidates for the treatment of the disease with fast-track and orphan drug classification.
During the forecast period, the high cost of development of the treatments or pharmaceuticals as well as the side effects connected with the therapy would act as a barrier to the growth of the market. Some of the potential adverse effects of treating neuroendocrine tumours include an increase in the patient's blood sugar level, the formation of gallstones, and minor discomfort in the digestive system in the form of bloating and nausea.
The market can be divided into the following categories based on site: gastrointestinal, lung, brain, and pancreatic, as well as additional categories.
As of right now, the part that represents the stomach has the largest proportion, followed by the segment that represents the lungs. Within the therapeutic treatment, category are subcategories such as chemotherapy, radiation therapy, and surgical procedures. In addition, the surgical procedure is subdivided into radiofrequency ablation (RFA), as well as local excision. Since it was discovered that radiofrequency ablation is the only treatment that may cure pancreatic NETs, it is anticipated that the market for this treatment would experience a significant increase. On the other hand, complications that may arise as a result of the procedure, such as pancreatic fistula, haemorrhage, and the spread of tumours, are likely to slow down its acceptance over the next several years. Excision at the local level is typically performed for kidney malignancies. Chemotherapy was shown to be the most effective treatment option for pancreatic NETs; however, there has not yet been a therapeutic option discovered that is effective in curing carcinoid tumours. When dealing with tumours that are developing slowly, it is often necessary to combine chemotherapy with surgical removal.
It is anticipated that the persistent efforts that pharmaceutical firms are making in order to create tailored medicine will increase demand. The medications streptozocin (Zanosar) and 5-fluorouracil (5-FU, Adrucil) are the ones that are utilized the most frequently in the treatment of neuroendocrine carcinomas. Targeted therapy has been gaining traction as a viable option for the treatment of this specific kind of cancer in recent years. For example, Everolimus (Afinitor) by Novartis and Sunitinib (Sutent) by Pfizer are two significant medications that are utilized for targeted therapy. Both companies manufacture these drugs. Drugs like these are employed in the treatment of renal cell carcinomas. Some of the compounds that are currently in the development stage for the treatment of NETs are Avastin, Atiprimod, and Lutathera.
The diagnostic instruments used in imaging, biopsy, serology, and other areas are taken into consideration while dividing up the market. The field of serology is broken down even further into subfields such as blood tests, urine tests, and molecular tests, among others. The imaging market may be further broken down into sub-markets such as CT scan, X-ray, PET scan, and others. The rising usage of improved diagnostic imaging methods that may identify extremely tiny malignant tumours that are clinically inconsequential is contributing to the rise of the imaging sector throughout the forecast period. This increase is expected to occur in the coming years.
It's generally agreed that the most lucrative market in North America. Because of the rising prevalence of NETs in the United States, this continent has become the top target for investment and the introduction of new products. Due to the vast patient population in this region, the United States is in top place internationally in terms of the number of clinical trials being conducted for NETs, followed by the United Kingdom. The National Health Service reported in 2015 that roughly 8,000 persons in the United Kingdom are diagnosed with a carcinoid tumour each and every year, and it is anticipated that this figure will continue to rise throughout the course of the projected period. This demonstrates the potential growth in demand for treatments for NETs in Europe over the next few years. Due to the rising prevalence of neuroendocrine tumours in Asia and the Pacific, the market for neuroendocrine carcinoma is expected to see profitable expansion in the coming years.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
"Find new revenue generation opportunities"